Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
äŒæ¥ã³ãŒãAMRN
äŒç€ŸåAmarin Corporation PLC
äžå Žæ¥Apr 01, 1993
æé«çµå¶è²¬ä»»è
ãCEOãBerg (Aaron D)
åŸæ¥å¡æ°275
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«Apr 01
æ¬ç€Ÿæåšå°WeWork One Central Plaza Dame Street
éœåžDUBLIN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIreland
éµäŸ¿çªå·D02 K7K5
é»è©±çªå·35316699020
ãŠã§ããµã€ãhttps://amarincorp.com/
äŒæ¥ã³ãŒãAMRN
äžå Žæ¥Apr 01, 1993
æé«çµå¶è²¬ä»»è
ãCEOãBerg (Aaron D)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã